Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off

por Yazici, Yusuf
Publicado 2012

Letter from the Editor

por Yazici, Yusuf
Publicado 2011

Informed consent: time for more transparency

por Yazici, Yusuf, Yazici, Hasan
Publicado 2010

Safety and clinical efficacy of golimumab in the treatment of arthritides

por Simsek, Ismail, Yazici, Yusuf
Publicado 2010

Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuring

por Yazici, Yusuf, Simsek, Ismail
Publicado 2013

Pragmatic assessment of exercise in routine care using an MDHAQ: associations with changes in RAPID3 and other clinical variables

por Castrejón, Isabel, Yazici, Yusuf, Celik, Selda, Pincus, Theodore
Publicado 2016

Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials

por Keystone, Edward C, Ahmad, Harris A, Yazici, Yusuf, Bergman, Martin J
Publicado 2020

Should quantitative assessment of rheumatoid arthritis include measures of joint damage and patient distress, in addition to measures of apparent inflammatory activity?

por Pincus, Theodore, Schmukler, Juan, Block, Joel A., Goodson, Nicola, Yazici, Yusuf
Publicado 2022

Asymptomatic giant coronary aneurysm in an adolescent with Behcet's syndrome

por Kahn, Philip J, Yazici, Yusuf, Argilla, Michael, Srichai, Monvadi, Levy, Deborah M
Publicado 2012

A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial

por Curtis, Jeffrey R., Herrem, Christopher, Ndlovu, ’Matladi N., O’Brien, Cathy, Yazici, Yusuf
Publicado 2017

MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology c...

por El-Haddad, Carlos, Castrejon, Isabel, Gibson, Kathryn A, Yazici, Yusuf, Bergman, Martin J, Pincus, Theodore
Publicado 2017

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

por Yazici, Yusuf, Xie, Lin, Ogbomo, Adesuwa, Ellis, Lorie A, Goyal, Kavitha, Teeple, Amanda, Simsek, Ismail
Publicado 2018

Utility of the new rheumatoid arthritis 2010 ACR/EULAR classification criteria in routine clinical care

por Kennish, Lauren, Labitigan, Monalyn, Budoff, Sam, Filopoulos, Maria T, McCracken, W Andrew, Swearingen, Christopher J, Yazici, Yusuf
Publicado 2012

Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration

por Schiff, Michael, Weinblatt, Michael E, Valente, Robert, Citera, Gustavo, Maldonado, Michael, Massarotti, Elena, Yazici, Yusuf, Fleischmann, Roy
Publicado 2016

Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial

por Tambiah, Jeyanesh R. S., Kennedy, Sarah, Swearingen, Christopher J., Simsek, Ismail, Yazici, Yusuf, Farr, Jack, Conaghan, Philip G.
Publicado 2021

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population

por Yazici, Yusuf, Xie, Lin, Ogbomo, Adesuwa, Ellis, Lorie A, Goyal, Kavitha, Teeple, Amanda, Mutlu, Ece A, Simsek, Ismail
Publicado 2018

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol

por Curtis, Jeffrey R., Churchill, Melvin, Kivitz, Alan, Samad, Ahmed, Gauer, Laura, Gervitz, Leon, Koetse, Willem, Melin, Jeffrey, Yazici, Yusuf
Publicado 2015

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials

por Strand, Vibeke, Lee, Eun Bong, Yazici, Yusuf, Dikranian, Ara, Wilkinson, Bethanie, Takiya, Liza, Zang, Chuanbo, Bananis, Eustratios, Bergman, Martin J.
Publicado 2018

Impact of apremilast on quality of life in Behçet’s syndrome: analysis of the phase 3 RELIEF study

por Hatemi, Gülen, Mahr, Alfred, Takeno, Mitsuhiro, Kim, Doyoung, Melikoğlu, Melike, Cheng, Sue, McCue, Shannon, Paris, Maria, Chen, Mindy, Yazici, Yusuf
Publicado 2022

Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open-label study

por Grayson, Peter C., Yazici, Yusuf, Merideth, Melissa, Sen, H. Nida, Davis, Michael, Novakovich, Elaine, Joyal, Elizabeth, Goldbach-Mansky, Raphaela, Sibley, Cailin H.
Publicado 2017